What is the current stock price of Genmab A/S (GNMSF)?

As of the latest market data, Genmab A/S (GNMSF) is trading at $281.75. The stock has seen a loss of 0.00% today.

Does Genmab A/S (GNMSF) pay a dividend?

Based on current data, Genmab A/S does not have a confirmed active dividend policy.

What is the market cap of Genmab A/S?

The current market capitalization of Genmab A/S (GNMSF) is approximately unavailable.

GNMSF

Genmab A/S·Healthcare

281.75

0.000%(+0.00)

Market Closed

298.55

5.963%(+16.80)

After Hours

Last Updated: — ET

52W L: $188.8052W H: $352.00

GNMSF NEWS

defenseworld.net

Mar 12

Genmab A/S (OTCMKTS:GNMSF) Stock Price Crosses Below 200 Day Moving Average – Here’s Why

Genmab A/S (OTCMKTS:GNMSF - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $305.26 and traded as low as $275.30. Genmab A/S shares last traded at $275.30, with a volume of 8 shares traded. Genmab A/S Trading Down 5.1% The

seekingalpha.com

Mar 11

Genmab A/S (GMAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

seekingalpha.com

Feb 17

Genmab A/S (GMAB) Q4 2025 Earnings Call Transcript

seekingalpha.com

Jan 29

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability to convert a strong backlog and increasingly sophisticated project mix into sustained earnings growth. We did not make any adjustments to the position and continue to believe that the market opportunity remains robust.

Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Sector

Healthcare

Industry

Biotechnology

Employees

2,638

IPO Date

2010-01-05

Beta

0.74

Websitewww.genmab.com↗